Related Experiment Video
Updated: Jan 30, 2026
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population
Athena F Zuppa1,2, Daniela J Conrado3, Nicole R Zane2
1Department of Pediatric Anesthesia and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.
Insights
This study developed a pharmacokinetic-pharmacogenomic model for midazolam in critically ill children, identifying genetic factors like UGT2B7 that influence drug clearance. This model aids in personalized sedation strategies for pediatric respiratory failure patients.
Area of Science:
- Pharmacology
- Genetics
- Critical Care Medicine
Background:
- Midazolam is commonly used for sedation in critically ill children.
- Understanding factors influencing midazolam pharmacokinetics is crucial for optimizing its use in pediatric intensive care units (PICUs).
- Pharmacogenomic factors can significantly impact drug metabolism and efficacy.
Purpose of the Study:
- To develop a population pharmacokinetic-pharmacogenomic model for midazolam in mechanically ventilated pediatric patients with respiratory failure.
- To identify nonheritable and heritable factors affecting midazolam pharmacokinetics.
- To provide a basis for individualized sedation approaches.
Main Methods:
- Prospective observational study in 13 US PICUs.
- Collected serial blood samples for drug and metabolite quantification and genetic analysis.
- Utilized nonlinear mixed-effects modeling to build the pharmacokinetic-pharmacogenomic model.
Main Results:
- Body weight, age, liver/kidney function, and UGT2B7 rs62298861 polymorphism predict midazolam pharmacokinetics.
- Midazolam clearance was estimated at 0.61 L/min/70kg.
- Minor alleles in UGT2B7 (rs62298861, rs28365062) were associated with higher 1'-hydroxymidazolam metabolite clearance in Caucasians, increasing clearance by 10-20%.
Conclusions:
- Developed a robust pharmacokinetic-pharmacogenomic model for midazolam in critically ill children.
- Identified key clinical and genetic predictors of midazolam disposition.
- The model supports the future implementation of personalized sedation strategies in pediatric critical care.
Objectives:
To develop a pharmacokinetic-pharmacogenomic population model of midazolam in critically ill children with primary respiratory failure.
Design:
Prospective pharmacokinetic-pharmacogenomic observational study.
Setting:
Thirteen PICUs across the United States.
Patients:
Pediatric subjects mechanically ventilated for acute respiratory failure, weight greater than or equal to 7 kg, receiving morphine and/or midazolam continuous infusions.
Interventions:
Serial blood sampling for drug quantification and a single blood collection for genomic evaluation.
Measurements And Main Results:
Concentrations of midazolam, the 1' (1`-hydroxymidazolam metabolite) and 4' (4`-hydroxymidazolam metabolite) hydroxyl, and the 1' and 4' glucuronide metabolites were measured. Subjects were genotyped using the Illumina HumanOmniExpress genome-wide single nucleotide polymorphism chip. Nonlinear mixed effects modeling was performed to develop the pharmacokinetic-pharmacogenomic model. Body weight, age, hepatic and renal functions, and the UGT2B7 rs62298861 polymorphism are relevant predictors of midazolam pharmacokinetic variables. The estimated midazolam clearance was 0.61 L/min/70kg. Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age. The final model suggested a decrease in midazolam clearance with increase in alanine transaminase and a lower clearance of the glucuronide metabolites with a renal dysfunction. In the pharmacogenomic analysis, rs62298861 and rs28365062 in the UGT2B7 gene were in high linkage disequilibrium. Minor alleles were associated with a higher 1`-hydroxymidazolam metabolite clearance in Caucasians. In the pharmacokinetic-pharmacogenomic model, clearance was expected to increase by 10% in heterozygous and 20% in homozygous for the minor allele with respect to homozygous for the major allele.
Conclusions:
This work leveraged available knowledge on nonheritable and heritable factors affecting midazolam pharmacokinetic in pediatric subjects with primary respiratory failure requiring mechanical ventilation, providing the basis for a future implementation of an individual-based approach to sedation.
More Related Videos
Related Concept Videos
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Acute Respiratory Failure-III
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Acute Respiratory Failure-IV